Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK5926371 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on GSK5926371, a putative trispecific antibody targeting CD19, MS4A1 (CD20), and CD3 (Jun 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK5926371 | GSK-5926371|GSK 5926371 | CD19 Antibody 24 CD20 Antibody 29 CD3 Antibody 126 | Limited information is currently available on GSK5926371, a putative trispecific antibody targeting CD19, MS4A1 (CD20), and CD3 (Jun 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07607925 | Phase Ib/II | GSK5926371 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | Not yet recruiting | USA | CAN | 1 |